{"ts": 1769035671.070826, "content": "[TABLE DATA]\nPipeline | Jernal | Date | Title | Link | PDF\nABL001 | mAbs | 2016 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |  | \nBMB Reports | 2020 | Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer |  | \nInt J Mol Sci | 2020 | ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models |  | \nPipeline | Name | Title | PDF\nABL001 | PEGS 2017 | Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 | \nASCO 2019 | Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer | \nPEPTALK 2020 | Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors | \n[END TABLE]\n\nABL Bio \ubcf8\ubb38\uc601\uc5ed \ubc14\ub85c\uac00\uae30 Pipeline ABL001 Home Pipeline ABL001 Overview ABL001 ABL105 ABL111 ABL301 ABL503 ABL202 Pipeline ABL001 Program Target VEGF x DLL4 Disease Indication Solid Tumor Development Stage Clinical Development (Phase 1a/1b) Summary Better anti-cancer efficacy of ABL001 at in vitro/in vivo studies are confirmed with cancer patients in clinical trial (phase 1a/1b). ABL001 can be developed as  the next generation of anti-angiogenic therapy. MOA of ABL001 Dual blockade of VEGF & DLL4 overcomes VEGF resistance POC of ABL001 in Preclinical Study Better efficacy compared to Avastin or anti-DLL4 monotherapy Clinical Response of ABL001 3 Patients showed confirmed partial response (PR) in phase 1a/1b study Publications Publications(Pipeline, Jernal, Date, Title, Link, PDF) Pipeline Jernal Date Title Link PDF ABL001 mAbs 2016 Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis BMB Reports 2020 Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer Int J Mol Sci 2020 ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models Posters Posters(Pipeline, Name, Title, PDF) Pipeline Name Title PDF ABL001 PEGS 2017 Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 ASCO 2019 Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer PEPTALK 2020 Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors ABL Bio About Us Who We Are History Corporate Identity Leadership Contact Us ESG Platform & Strategies Platform Oncology Strategy CNS Disease Strategy ADC Strategy Publications Pipeline Overview ABL301 ABL503 ABL111 ABL102 ABL103 ABL104 ABL105 Investors & Media Public Disclosure Stock Information Finance Information Notice News Document & Materials Careers Core Competencies Benefits Recruitment Recruiting Process \uba54\ub274\ub2eb\uae30", "type": "text"}